Platelet

Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Retrieved on: 
Jeudi, novembre 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Risk, Platelet, International, Publication, Society, Neonatal alloimmune thrombocytopenia, Poster, ASH, Corporation, Dietary supplement

Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study has been accepted for poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting, which will be held December 9-12, 2023, in San Diego, California.

Key Points: 
  • Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study has been accepted for poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting, which will be held December 9-12, 2023, in San Diego, California.
  • Details of the poster presentation are as follows:
    Title: Identifying Pregnancies at Higher Risk for HPA-1a Alloimmunization and Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT): An International, Prospective, Natural History Study
    Session Name: 311.
  • Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I
    The abstract is available on the ASH Annual Meeting website .
  • Following presentation at the meeting, the poster will be accessible via the Publications and Presentations section of Rallybio’s website www.rallybio.com .

Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Jeudi, novembre 2, 2023
CR, IVO, VEN, Haematopoiesis, Constipation, Platelet, Acute myeloid leukemia, CRC, Prior, Thrombocytopenia, Vomiting, MDS, Diarrhea, Treatment, Rigel, Fostamatinib, Bone marrow, Hematopoietic stem cell transplantation, CRH, CRi, Inflammation, Azacitidine, Nausea, Society, Progress, ASH, Poster, Myelodysplastic syndrome, Cell death, Relapse, ITP, SAN, ORR, University, Safety, Venetoclax, IRAK, Cellular, MD Anderson Cancer Center, Cytopenia, Transplant, Neutropenia, AML, HSCT, Fatigue, Pharmaceutical industry, Dentistry, Dietary supplement, Bookkeeping, Vaccine, Patient, Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of four posters highlighting data from their commercial and clinical-stage hematology-oncology portfolio at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, California and virtually.

Key Points: 
  • "We are also excited by the compelling data in patients with mIDH1 MDS and look forward to evaluating this potential opportunity further.
  • On top of the olutasidenib data, we are delighted to share other updates and data across our development portfolio, demonstrating our presence in the hematology-oncology space."
  • These results support the use of fostamatinib as a second-line treatment in patients with primary ITP.
  • To learn more about Rigel Pharmaceuticals and their clinical and commercial hematology/oncology portfolio visit Booth #2805 during ASH 2023.

Access Vascular Highlights New Bacterial Adhesion Data at AVA 2023

Retrieved on: 
Mardi, octobre 17, 2023
Nursing, Medical Devices, Surgery, Medical Supplies, Hospitals, Cardiology, Practice Management, Biotechnology, Managed Care, Health, PICC, Biomaterial, COVID-19, Hospital, AVA, CLABSI, Platelet, Standard of care, AVI, Bacterial adhesion in aquatic system, Risk, Thrombus, HBM, CMS, Journal, Catheter, Patient, Medical device

Access Vascular, Inc. (AVI) , a company addressing the most common and costly vascular access complications with its advanced biomaterial platform, today announced findings from a new, in vitro study showing a significant reduction in bacterial adhesion and thrombus accumulation in peripherally inserted central catheters (PICC) and midline catheters with AVI’s MIMIX™ hydrophilic biomaterial (HBM).

Key Points: 
  • Access Vascular, Inc. (AVI) , a company addressing the most common and costly vascular access complications with its advanced biomaterial platform, today announced findings from a new, in vitro study showing a significant reduction in bacterial adhesion and thrombus accumulation in peripherally inserted central catheters (PICC) and midline catheters with AVI’s MIMIX™ hydrophilic biomaterial (HBM).
  • The HBM demonstrated a 99.998 percent reduction in bacterial adhesion compared with the standard polyurethane catheter, and a 99.989 percent reduction compared with an augmented polyurethane material.
  • These findings are consistent with previously reported in vitro data on thrombus accumulation, based on platelet count,iv,v with the HBM catheter.
  • “These results highlight the potential for catheters made from MIMIX™ to reduce bacterial adhesion, which often leads to central-line associated bloodstream infections (CLABSI) and has devastating implications for already sick patients,” said James Biggins, CEO of Access Vascular.

Nerviano Medical Sciences Presents Preliminary, Encouraging Clinical Phase 1 Data for PARP-1 Selective Inhibitor at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Jeudi, octobre 12, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, NMS, TMZ, Medicine, Weakness, Doctor of Philosophy, Vomiting, BID, Brain, AACR, Platelet, MD, MTD, Aplastic anemia, Safety, Nausea, PARP, Phase, Appetite, Fatigue, BRCA, Trae tha Truth, Temozolomide, MGMT, Neoplasm, Infrared spectroscopy correlation table, Overalls, QT interval, Glioblastoma, Glioma, Doctor of Pharmacy, S.P. Tre Penne, Patient, Poster, Pharmaceutical industry

As an oral, brain penetrant PARP-1 selective inhibitor, NMS-293 has shown strong antitumor activity and complete tumor regression in BRCA mutated preclinical models as a single agent.

Key Points: 
  • As an oral, brain penetrant PARP-1 selective inhibitor, NMS-293 has shown strong antitumor activity and complete tumor regression in BRCA mutated preclinical models as a single agent.
  • NMS-293 shows remarkable selectivity towards PARP-1 and efficiently inhibits cellular PARP activity resulting in selective antiproliferative responses on BRCA mutated cell lines.
  • Furthermore, NMS-293 is synergistic and well tolerated in combination with temozolomide (TMZ) in both MGMT methylated and MGMT unmethylated glioblastoma mouse models.
  • For the first time, clinical data is being presented during the poster session (Abstract 37568) at the AACR-NCI-EORTC 2023 Annual Meeting in Boston, Massachusetts.

Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates

Retrieved on: 
Mercredi, septembre 6, 2023
Tacrolimus, Survival, American Society of Nephrology, Platelet, ASN, Congress, Incidence, Patient, Standard of care, Vivo, Risk, Organ transplantation, Primate, Immune system, Science Translational Medicine, Kidney, Kidney transplantation, Eledone, CD40L, Society, Safety, Pharmaceutical industry, Nephrology, FC

IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the publication of a study evaluating tegoprubart as an immunomodulatory monotherapy in nonhuman primate kidney and islet allotransplants.

Key Points: 
  • IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the publication of a study evaluating tegoprubart as an immunomodulatory monotherapy in nonhuman primate kidney and islet allotransplants.
  • The study, entitled “The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates”, was published in the August 30, 2023, issue of Science Translational Medicine.
  • Results from the study showed that treatment with tegoprubart as a monotherapy promoted long-term kidney and islet allograft survival and function in nonhuman primates, indicating its potential as an immunomodulatory agent for organ transplantation.
  • Eledon expects to report updated clinical data from the Phase 1b study at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in November 2023.

Essential Thrombocythemia Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Imago BioSciences, Incyte, Karyopharm, Novartis, PharmaEssentia, Celgene, Kartos, Sierra Oncology

Retrieved on: 
Mercredi, août 30, 2023
GSK plc, Disease, Headache, Essential thrombocythemia, Bleeding, Prevalence, Conditional sentence, Hydroxycarbamide, Bone marrow, Genetic testing, Platelet, Petechia, Aspirin, Common, LAS, Bruise, Dizziness, Spleen, Novartis, Patient, Risk, Physiology, Plateletpheresis, Blood, MMB, CTI, Thrombocythemia, United Kingdom, Abdomen, Diagnosis, Oncology, Haematopoietic system, Skin, Medical device, Medical imaging, Pacritinib, Momelotinib, Ropeginterferon alfa-2b

LAS VEGAS, Aug. 30, 2023 /PRNewswire/ -- DelveInsight's Essential Thrombocythemia Market Insights report includes a comprehensive understanding of current treatment practices, essential thrombocythemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • These factors along with the expected launch of emerging therapies will boost the essential thrombocythemia market in the forecasted period.
  • As per DelveInsight analysts, total prevalent population of essential thrombocythemia in the 7MM was 240K in 2020.
  • Estimates observed that the age-group 60-80 years accounted for highest cases of essential thrombocythemia in the United States.
  • To know more about essential thrombocythemia treatment, visit @ Essential Thrombocythemia Treatment Drugs

Essential Thrombocythemia Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Imago BioSciences, Incyte, Karyopharm, Novartis, PharmaEssentia, Celgene, Kartos, Sierra Oncology

Retrieved on: 
Mercredi, août 30, 2023
GSK plc, Disease, Headache, Essential thrombocythemia, Bleeding, Prevalence, Conditional sentence, Hydroxycarbamide, Bone marrow, Genetic testing, Platelet, Petechia, Aspirin, Common, LAS, Bruise, Dizziness, Spleen, Novartis, Patient, Risk, Physiology, Plateletpheresis, Blood, MMB, CTI, Thrombocythemia, United Kingdom, Abdomen, Diagnosis, Oncology, Haematopoietic system, Skin, Medical device, Medical imaging, Pacritinib, Momelotinib, Ropeginterferon alfa-2b

LAS VEGAS, Aug. 30, 2023 /PRNewswire/ -- DelveInsight's Essential Thrombocythemia Market Insights report includes a comprehensive understanding of current treatment practices, essential thrombocythemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • These factors along with the expected launch of emerging therapies will boost the essential thrombocythemia market in the forecasted period.
  • As per DelveInsight analysts, total prevalent population of essential thrombocythemia in the 7MM was 240K in 2020.
  • Estimates observed that the age-group 60-80 years accounted for highest cases of essential thrombocythemia in the United States.
  • To know more about essential thrombocythemia treatment, visit @ Essential Thrombocythemia Treatment Drugs

JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients

Retrieved on: 
Mercredi, juillet 19, 2023
Maintenance, Progression-free survival, Platelet, ISD, Survival, Woman, PRIME, PFS, JAMA Oncology, HKEX, Hospital, HIV disease progression rates, Patient, Risk, Neoplasm, Ovarian cancer, Recurrence, ITT, Death, PARP, Pharmaceutical industry

SHANGHAI, China and CAMBRIDGE, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that JAMA Oncology published data from the pivotal Phase 3 PRIME study evaluating ZEJULA® (niraparib) as a first-line maintenance therapy in Chinese patients with newly diagnosed advanced ovarian cancer. These data demonstrate that maintenance treatment with ZEJULA significantly prolongs progression-free survival (PFS) versus placebo and reduces the risk of disease progression or death by 55%. These findings are consistent with prior studies that indicate that front-line maintenance therapy with ZEJULA can provide statistically and clinically meaningful benefit in a broad population of patients, regardless of postoperative residual disease or biomarker status.

Key Points: 
  • These data demonstrate that maintenance treatment with ZEJULA significantly prolongs progression-free survival (PFS) versus placebo and reduces the risk of disease progression or death by 55%.
  • These findings are consistent with prior studies that indicate that front-line maintenance therapy with ZEJULA can provide statistically and clinically meaningful benefit in a broad population of patients, regardless of postoperative residual disease or biomarker status.
  • “The positive results from the PRIME study, which show a substantial reduction in risk of disease progression or death with ZEJULA maintenance, offer insights into the potential to delay the progression of this devastating disease in a broad group of patients.
  • At the time of data cut-off, overall survival (OS) data were not yet mature in the ITT population.

Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R

Retrieved on: 
Lundi, juin 26, 2023
Tissue, PK, Radiation, Society, Arm, Radioactive decay, SNMMI, Megakaryocyte, Cohort, TAT, PSMA, Molecular imaging, Platelet, Therapeutic index, Society of Nuclear Medicine and Molecular Imaging, Pharmacokinetics, Toxicity, Șaeș, Patient, Memorial Sloan Kettering Cancer Center, Kidney, Liver, ADC, Infrared spectroscopy correlation table, Spacecraft, Tat, Thrombocytopenia, Conference, Safety, Vaccine, Medical imaging, Lithium, Fusion

HAMILTON, ON and BOSTON, June 26, 2023 /PRNewswire/ --  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of interim data from the dose escalation portion of the Phase 1 trial of [225Ac]-FPI-1434 (FPI-1434) in patients with solid tumors expressing IGF-1R. The data will be presented by Neeta Pandit-Taskar, M.D., of Memorial Sloan Kettering Cancer Center, tomorrow at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting and will include molecular imaging, safety and pharmacokinetics (PK) from two dosing regimens: one with FPI-1434 alone ("hot only"), and another in which a small dose of cold antibody (naked IGF-1R antibody without the isotope) is administered prior to each dose of FPI-1434 ("cold/hot"). The poster presentation is available via the SNMMI Annual Meeting mobile application.

Key Points: 
  • "Antibody drug conjugates (ADCs) have shown tremendous success recently, driven in part by the benefits of using more potent payloads.
  • The Phase 1, multi-center, open-label clinical trial is designed to investigate the safety, tolerability and pharmacokinetics of FPI-1434 in patients with solid tumors expressing IGF-1R.
  • The trial is also designed to establish the maximum tolerated dose for FPI-1434 and the recommended Phase 2 dose.
  • To access the live call, please dial 1-877-870-4263 (U.S.), 1-855-669-9657 (Canada) or 1-412-317-0790 (international) and reference Fusion Pharmaceuticals.

Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2023 Hybrid Congress

Retrieved on: 
Lundi, juin 12, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Abstract, Rituximab, PCNSL, European Hematology Association, DLBCL, Glucocorticoid, Platelet, Lymphoma, Sequence, ITP, Trae Waynes, SSE, Clinical research associate, HKEX, Patient, Randomness, EHA, IVIG, GC, Primary central nervous system lymphoma, ORR, Safety, Medical imaging

Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2023 Hybrid Congress.

Key Points: 
  • Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2023 Hybrid Congress.
  • As of cut-off date on 6 Feb 2023, 33 patients were enrolled.
  • Both 50mg QD and 30mg QD of orelabrutinib were safe in the treatment of patients with ITP.
  • Among the 22 patients with previous response to GC or IVIG, 75.0% at the 50mg arm achieved the primary endpoint.